drugset / Trial / NCT02411708
Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis
RandomizedParallel-groupSingle-blindTreatment
Summary
Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis
Timeline
- Start
- 2016-11
- Primary completion
- 2017-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pegylated carboxyhemoglobin bovine | Protein / enzyme biologic | 320 mg/kg | — |